Events & Presentations
Presentations
| Date | Title | Documents |
|---|---|---|
RedHill Biopharma Corporate Presentation |
|
Featured Events
| Date | Event Details | Remind Me |
|---|---|---|
|
Oct 22, 2018
|
United European Gastroenterology Week (UEG Week 2018)
Vienna, Austria
An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study. |
|
|
Dec 29, 2015
|
Prof. Thomas Borody Interview on Crohn's Disease and Gut Health
|
Upcoming Events & Presentations
| Date | Event Details | Remind Me |
|---|---|---|
|
Nov 19, 2019
8:30 AM EST |
Third Quarter 2019 Financial Results Conference Call
Please dial one of the following numbers 15 minutes prior to the start of the call:
United States: +1-866-966-1396 International: +1-631-510-7495 Israel: +972-3-721-7998 Access code: 8998611 |
|
|
Nov 22, 2019
8:00 AM EST |
RedHill Investor and Analyst Breakfast
New York
The event will feature presentations from RedHill's management team who will provide an overview of the Company's U.S. commercial strategy for launching Talicia® and Aemcolo®. RedHill’s expects to launch Aemcolo® in Q4/19 and Talicia® in Q1/20 with its expanding dedicated sales force.
Management will be available to answer questions at the conclusion of the event.
For further information please contact: investors@redhillbio.com |